C4 Therapeutics share price today

(CCCC)

C4 Therapeutics share price is $3.66 & ₹313.81 as on 3 Jan 2025, 2.30 'hrs' IST

$3.66

▲

0.06

(1.67%)

Market is closed - opens 8 PM, 03 Jan 2025

View live C4 Therapeutics share price in Dollar and Rupees. Guide to invest in C4 Therapeutics from India. Also see the sentimental analysis on Indian investors investing in C4 Therapeutics. Get details on the Indian mutual funds that are investing in C4 Therapeutics. Get Analyst recommendations and forecasts along with all the C4 Therapeutics's financials.

C4 Therapeutics share price movements

Today's Low: $3.56
Today's High: $3.87
$3.66
2.73%
Downside
Day's Volatility :8.01%
Upside
5.43%
52 Weeks Low: $3.43
52 Weeks High: $11.88
$3.66
6.28%
Downside
52 Weeks Volatility :71.13%
Upside
69.19%

C4 Therapeutics Returns

Period	C4 Therapeutics, Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-33.09%	-10.0%	0.0%
6 Months	-20.35%	-4.7%	0.0%
1 Year	-43.22%	-0.9%	0.0%
3 Years	-88.6%	-2.4%	-21.2%

C4 Therapeutics Key Statistics

in dollars & INR

Previous Close	$3.6
Open	$3.59
Today's High	$3.87
Today's Low	$3.56
Market Capitalization	$254.1M
Today's Volume	$1.2M
52 Week High	$11.88
52 Week Low	$3.43
Revenue TTM	$33.7M
EBITDA	$-115.1M
Earnings Per Share (EPS)	$-1.71
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-46.0%

How to invest in C4 Therapeutics from India?

It is very easy for Indian residents to invest directly in C4 Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the C4 Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for C4 Therapeutics or CCCC on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of C4 Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of C4 Therapeutics shares which would translate to 0.234 fractional shares of C4 Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like C4 Therapeutics, in just a few clicks!

Returns in C4 Therapeutics for Indian investors in Rupees

Investment Value

₹1,00,000

C4 Therapeutics investment value today

Current value as on today

₹60,704

Returns

₹39,296

(-39.3%)

Returns from C4 Therapeutics Stock

₹42,271 (-42.27%)

Dollar Returns

₹2,975 (+2.97%)

Indian investors sentiment towards C4 Therapeutics

181%

Period: Oct 4, 2024 to Jan 2, 2025. Change in 30 Days versus previous period

Search volume for C4 Therapeutics on INDmoney from India has grown in the last 30 days as on Jan 3, 2025. 181% more investors are searching C4 Therapeutics in the last 30 days versus the previous period.

Global Institutional Holdings in C4 Therapeutics

Soleus Capital Management, L.P.
9.36%
Wasatch Advisors LP
8.04%
RA Capital Management, LLC
6.91%
BlackRock Inc
6.45%
Orbimed Advisors, LLC
6.20%
COMMODORE CAPITAL LP
4.83%

Analyst Recommendation on C4 Therapeutics

Buy

73%Buy

26%Hold

0%Sell

Based on 15 Wall street analysts offering stock ratings for C4 Therapeutics(by analysts ranked 0 to 5 stars)

Based on 15 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on C4 Therapeutics

What analysts predicted

Upside of 309.84%

Current:

$3.66

Target:

$15.00

Insights on C4 Therapeutics

Price Movement
In the last 7 days, CCCC stock has moved down by -10.0%
Increasing Revenue
Revenue is up for the last 3 quarters, 3.03M → 15.36M (in $), with an average increase of 48.3% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -17.71M → -24.66M (in $), with an average decrease of 39.2% per quarter
CCCC vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 20.7% return, outperforming this stock by 65.5%
CCCC vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 38.8% return, outperforming this stock by 127.6%
Price to Sales
ForCCCC every $1 of sales, investors are willing to pay $6.9, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.2 for every $1 of sales.

C4 Therapeutics Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$19.4M	-
Net Income	$-15.7M	-
Net Profit Margin	-81.14%	-

	FY19	Y/Y Change
Revenue	$21.4M	↑ 10.42%
Net Income	$-34.1M	↑ 117.04%
Net Profit Margin	-159.48%	↓ 78.34%

	FY20	Y/Y Change
Revenue	$33.2M	↑ 55.25%
Net Income	$-66.3M	↑ 94.54%
Net Profit Margin	-199.83%	↓ 40.35%

	FY21	Y/Y Change
Revenue	$45.8M	↑ 37.93%
Net Income	$-86.0M	↑ 29.7%
Net Profit Margin	-187.92%	↑ 11.91%

	FY22	Y/Y Change
Revenue	$31.1M	↓ 32.08%
Net Income	$-126.5M	↑ 47.03%
Net Profit Margin	-406.8%	↓ 218.88%

	FY23	Y/Y Change
Revenue	$20.8M	↓ 33.25%
Net Income	$-132.5M	↑ 4.74%
Net Profit Margin	-638.34%	↓ 231.54%

	Q2 FY23	Q/Q Change
Revenue	$2.7M	↓ 29.13%
Net Income	$-35.9M	↑ 5.85%
Net Profit Margin	-1.3K%	↓ 445.57%

	Q3 FY23	Q/Q Change
Revenue	$11.1M	↑ 315.62%
Net Income	$-27.0M	↓ 24.73%
Net Profit Margin	-244.19%	↑ 1104.23%

	Q4 FY23	Q/Q Change
Revenue	$3.3M	↓ 70.55%
Net Income	$-34.8M	↑ 28.54%
Net Profit Margin	-1.1K%	↓ 821.56%

	Q1 FY24	Q/Q Change
Revenue	$3.0M	↓ 6.81%
Net Income	$-28.4M	↓ 18.4%
Net Profit Margin	-933.23%	↑ 132.52%

	Q2 FY24	Q/Q Change
Revenue	$12.0M	↑ 295.06%
Net Income	$-17.7M	↓ 37.53%
Net Profit Margin	-147.56%	↑ 785.67%

	Q3 FY24	Q/Q Change
Revenue	$15.4M	↑ 27.95%
Net Income	$-24.7M	↑ 39.23%
Net Profit Margin	-160.57%	↓ 13.01%

	FY18	Y/Y Change
Profit	$19.4M	-

	FY19	Y/Y Change
Profit	$-26.3M	↓ 235.73%

	FY20	Y/Y Change
Profit	$-44.3M	↑ 68.45%

	FY21	Y/Y Change
Profit	$42.9M	↓ 196.85%

	FY22	Y/Y Change
Profit	$23.5M	↓ 45.14%

	FY23	Y/Y Change
Profit	$-97.0M	↓ 512.13%

	Q2 FY23	Q/Q Change
Profit	$675.0K	↓ 60.22%

	Q3 FY23	Q/Q Change
Profit	$9.1M	↑ 1244.74%

	Q4 FY23	Q/Q Change
Profit	$1.6M	↓ 82.7%

	Q1 FY24	Q/Q Change
Profit	$1.0M	↓ 35.54%

	Q2 FY24	Q/Q Change
Profit	$10.0M	↑ 884.29%

	Q3 FY24	Q/Q Change
Profit	$13.3M	↑ 33.58%

	FY18	Y/Y Change
Operating Cash Flow	$-17.0M	-
Investing Cash Flow	$36.9M	-
Financing Cash Flow	$2.0M	-

	FY19	Y/Y Change
Operating Cash Flow	$55.6M	↓ 427.51%
Investing Cash Flow	$-1.6M	↓ 104.39%
Financing Cash Flow	$244.0K	↓ 87.56%

	FY20	Y/Y Change
Operating Cash Flow	$-67.2M	↓ 220.92%
Investing Cash Flow	$-190.5M	↑ 11659.57%
Financing Cash Flow	$348.9M	↑ 142904.92%

	FY21	Y/Y Change
Operating Cash Flow	$-87.0M	↑ 29.32%
Investing Cash Flow	$-189.3M	↓ 0.61%
Financing Cash Flow	$171.4M	↓ 50.88%

	FY22	Y/Y Change
Operating Cash Flow	$-105.9M	↑ 21.82%
Investing Cash Flow	$58.4M	↓ 130.86%
Financing Cash Flow	$1.1M	↓ 99.33%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-19.0M	↓ 42.65%
Investing Cash Flow	$15.1M	↑ 0.0%
Financing Cash Flow	$-746.0K	↑ 9.06%

C4 Therapeutics Technicals Summary

Sell

Neutral

Buy

C4 Therapeutics is currently in a neutral trading position according to technical analysis indicators.

C4 Therapeutics Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
C4 Therapeutics, Inc	-7.93%	-20.35%	-43.22%	-88.6%	-85.88%
Regeneron Pharmaceuticals, Inc.	-4.97%	-31.12%	-21.91%	15.48%	91.62%
Biontech Se	-1.42%	42.28%	6.01%	-49.15%	155.61%
Alnylam Pharmaceuticals, Inc.	-6.56%	-6.26%	22.36%	42.41%	102.91%
Vertex Pharmaceuticals Incorporated	-11.88%	-15.14%	-3.23%	81.51%	79.75%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
C4 Therapeutics, Inc	NA	NA	NA	-1.36	-0.46	-0.21	NA	3.44
Regeneron Pharmaceuticals, Inc.	17.61	17.61	1.06	45.07	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.11	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.06	0.51	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
C4 Therapeutics, Inc	Buy	$254.1M	-85.88%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$78.3B	91.62%	17.61	33.61%
Biontech Se	Buy	$27.3B	155.61%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$30.4B	102.91%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$103.7B	79.75%	32.84	-4.51%

About C4 Therapeutics

c4 therapeutics is an early stage drug discovery company whose mission is to harness targeted protein degradation to develop therapeutics for a broad range of diseases. the centerpiece of our approach is the degronimid® platform, which enables highly selective small molecule binders to target disease causing proteins and facilitate their rapid destruction and clearance from the cell through the natural ubiquitin/proteasome system.

Organization	C4 Therapeutics
Employees	145
CEO	Mr. Andrew J. Hirsch M.B.A.
Industry	Health Technology

Management People of C4 Therapeutics

Name	Title
Mr. Andrew J. Hirsch M.B.A.	CEO, President & Director
Dr. Kenneth C. Anderson M.D., Ph.D.	Co-Founder, Independent Director & Member of Scientific Advisory Board
Dr. Leonard M. J. Reyno M.D.	Chief Medical Officer
Dr. Nathanael S. Gray Ph.D.	Co-Founder & Member of Scientific Advisory Board
Ms. Kendra Adams	CFO & Treasurer
Mr. Mark Mossler	Chief Accounting Officer
Ms. Paige Mahaney Ph.D.	Chief Scientific Officer
Ms. Courtney Solberg	Senior Manager of Investor Relations
Ms. Jolie M. Siegel J.D.	Chief Legal Officer & Corporate Secretary
Ms. Kelly A. Schick	Chief People Officer

Important FAQs about investing in C4 Therapeutics from India :

What is C4 Therapeutics share price today?

C4 Therapeutics share price today stands at $3.66, Open: $3.59 ; Previous Close: $3.60 ; High: $3.87 ; Low: $3.56 ; 52 Week High: $11.88 ; 52 Week Low: $3.43. The stock opens at $3.59, after a previous close of $3.60. The stock reached a daily high of $3.87 and a low of $3.56, with a 52-week high of $11.88 and a 52-week low of $3.43.

Can Indians buy C4 Therapeutics shares?

Yes, Indians can invest in the C4 Therapeutics (CCCC) from India.

With INDmoney, you can buy C4 Therapeutics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy C4 Therapeutics at zero transaction cost.

How can I buy C4 Therapeutics shares from India?

It is very easy to buy C4 Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of C4 Therapeutics be purchased?

Yes, you can buy fractional shares of C4 Therapeutics with INDmoney app.

What are the documents required to start investing in C4 Therapeutics stocks?

To start investing in C4 Therapeutics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.